Thamer M - Search Results

1

Long-Term Outcomes of Arteriovenous Fistulas with Unassisted versus Assisted Maturation: A Retrospective National Hemodialysis Cohort Study.

Lee T, Qian JZ, Zhang Y, Thamer M, Allon M. Lee T, et al. Among authors: thamer m. J Am Soc Nephrol. 2019 Nov;30(11):2209-2218. doi: 10.1681/ASN.2019030318. Epub 2019 Oct 14. J Am Soc Nephrol. 2019. PMID: 31611240 Free PMC article.

2

Epoetin requirements predict mortality in hemodialysis patients.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Zhang Y, et al. Among authors: thamer m. Am J Kidney Dis. 2004 Nov;44(5):866-76. Am J Kidney Dis. 2004. PMID: 15492953

3

Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.

Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Cotter DJ, et al. Among authors: thamer m. J Clin Epidemiol. 2004 Oct;57(10):1086-95. doi: 10.1016/j.jclinepi.2004.05.002. J Clin Epidemiol. 2004. PMID: 15528060

4

Time to consider the role of epoetin.

Zhang Y, Thamer M. Zhang Y, et al. Among authors: thamer m. Kidney Int. 2006 May;69(10):1917; author reply 1917-8. doi: 10.1038/sj.ki.5000364. Kidney Int. 2006. PMID: 16688199 Free article. No abstract available.

5

Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.

Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ. Thamer M, et al. Am J Kidney Dis. 2006 Jul;48(1):77-87. doi: 10.1053/j.ajkd.2006.03.040. Am J Kidney Dis. 2006. PMID: 16797389

6

Translating epoetin research into practice: the role of government and the use of scientific evidence.

Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. Cotter D, et al. Among authors: thamer m. Health Aff (Millwood). 2006 Sep-Oct;25(5):1249-59. doi: 10.1377/hlthaff.25.5.1249. Health Aff (Millwood). 2006. PMID: 16966720

7

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA. Thamer M, et al. JAMA. 2007 Apr 18;297(15):1667-74. doi: 10.1001/jama.297.15.1667. JAMA. 2007. PMID: 17440144

8

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.

Thamer M, Zhang Y, Kaufman J, Cotter D, Hernán MA. Thamer M, et al. Am J Kidney Dis. 2007 Oct;50(4):538-41. doi: 10.1053/j.ajkd.2007.08.001. Am J Kidney Dis. 2007. PMID: 17900452 No abstract available.

9

The effect of epoetin dose on hematocrit.

Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA. Cotter D, et al. Among authors: thamer m. Kidney Int. 2008 Feb;73(3):347-53. doi: 10.1038/sj.ki.5002688. Epub 2007 Nov 14. Kidney Int. 2008. PMID: 18004296 Free article.

10

Relative mortality and epoetin alpha dose in hemodialysis patients.

Cotter DJ, Thamer M, Zhang Y. Cotter DJ, et al. Among authors: thamer m. Am J Kidney Dis. 2008 May;51(5):865; author reply 865-6. doi: 10.1053/j.ajkd.2007.12.045. Am J Kidney Dis. 2008. PMID: 18436099 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page